Physician profile
Mark W Root
NPI 1285647602
$500.52
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $18.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $333.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $46.42 | 2019 | |
| Lundbeck LLC | $32.26 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $22.08 | 2019 | |
| Jazz Pharmaceuticals INC. | $20.61 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.92 | 2019 | |
| Shire North American Group INC | $13.93 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.33 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Root listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.